CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the appointment of Tomas S. Bocanegra, M.D., as Executive Vice President of Development. Dr. Bocanegra will be responsible for driving all product development activities at POZEN, beginning with the Company’s lead pipeline candidate, PA32540, a coordinated-delivery tablet of enteric-coated aspirin and immediate-release omeprazole. This novel, patented oral product is currently in Phase 3 clinical development in the United States with New Drug Application (NDA) submission scheduled for 2012.
